

**AMENDMENT IN THE NATURE OF A SUBSTITUTE  
TO H.R. 2505**

**[Greenwood/Deutsch/DeGette/Schiff Amendment]**

**OFFERED BY MR. GREENWOOD OF PENNSYLVANIA**

Strike all after the enacting clause and insert the following:

**1 SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Cloning Prohibition  
3 Act of 2001”.

**4 SEC. 2. PROHIBITION AGAINST HUMAN CLONING.**

5 (a) IN GENERAL.—The Federal Food, Drug, and  
6 Cosmetic Act (21 U.S.C. 301 et seq.) is amended by add-  
7 ing at the end the following:

8 “CHAPTER X—HUMAN CLONING

9 “PROHIBITION AGAINST HUMAN CLONING

10 “SEC. 1001. (a) NUCLEAR TRANSFER TECH-  
11 NOLOGY.—

12 “(1) IN GENERAL.—It shall be unlawful for any  
13 person—

14 “(A) to use or attempt to use human so-  
15 matic cell nuclear transfer technology, or the  
16 product of such technology, to initiate a preg-



1 nancy or with the intent to initiate a pregnancy;

2 or

3 “(B) to ship, mail, transport, or receive the  
4 product of such technology knowing that the  
5 product is intended to be used to initiate a  
6 pregnancy.

7 “(2) DEFINITION.—For purposes of this sec-  
8 tion, the term ‘human somatic cell nuclear transfer  
9 technology’ means transferring the nuclear material  
10 of a human somatic cell into an egg cell from which  
11 the nuclear material has been removed or rendered  
12 inert.

13 “(b) RULE OF CONSTRUCTION.—This section may  
14 not be construed as applying to any of the following:

15 “(1) The use of somatic cell nuclear transfer  
16 technology to clone molecules, DNA, cells, or tissues.

17 “(2) The use of mitochondrial, cytoplasmic, or  
18 gene therapy.

19 “(3) The use of in vitro fertilization, the admin-  
20 istration of fertility-enhancing drugs, or the use of  
21 other medical procedures (excluding those using  
22 human somatic cell nuclear transfer or the product  
23 thereof) to assist a woman in becoming or remaining  
24 pregnant



1           “(4) The use of somatic cell nuclear transfer  
2           technology to clone or otherwise create animals other  
3           than humans.

4           “(5) Any other activity (including biomedical,  
5           microbiological, or agricultural research or practices)  
6           not expressly prohibited in subsection (a).

7           “(c) REGISTRATION.—

8           “(1) IN GENERAL.—Each individual who in-  
9           tends to perform human somatic cell nuclear trans-  
10          fer technology shall, prior to first performing such  
11          technology, register with the Secretary his or her  
12          name and place of business (except that, in the case  
13          of an individual who performed such technology be-  
14          fore the date of the enactment of the Cloning Prohi-  
15          bition Act of 2001, the individual shall so register  
16          not later than 60 days after such date). The Sec-  
17          retary may by regulation require that the registra-  
18          tion provide additional information regarding the  
19          identity and business locations of the individual, and  
20          information on the training and experience of the in-  
21          dividual regarding the performance of such tech-  
22          nology.

23          “(2) ATTESTATION.—A registration under  
24          paragraph (1) shall include a statement, signed by  
25          the individual submitting the registration, declaring



1 that the individual is aware of the prohibitions de-  
2 scribed in subsection (a) and will not engage in any  
3 violation of such subsection.

4 “(3) CONFIDENTIALITY.—Information provided  
5 in a registration under paragraph (1) shall not be  
6 disclosed to the public by the Secretary except to the  
7 extent that—

8 “(A) the individual submitting the reg-  
9 istration has in writing authorized the disclo-  
10 sure; or

11 “(B) the disclosure does not identify such  
12 individual or any place of business of the indi-  
13 vidual.

14 “(d) PREEMPTION OF STATE LAW.—This section su-  
15 persedes any State or local law that—

16 “(1) establishes prohibitions, requirements, or  
17 authorizations regarding human somatic cell nuclear  
18 transfer technology that are different than, or in ad-  
19 dition to, those established in subsection (a) or (c);  
20 or

21 “(2) with respect to humans, prohibits or re-  
22 stricts research regarding or practices constituting—

23 “(A) somatic cell nuclear transfer;

24 “(B) mitochondrial or cytoplasmic therapy;

25 or



1                   “(C) the cloning of molecules, DNA, cells,  
2                   tissues, or organs;  
3                   except that this subsection does not apply to any State  
4                   or local law that was in effect as of the day before the  
5                   date of the enactment of the Cloning Prohibition Act of  
6                   2001.

7                   “(e) RIGHT OF ACTION.—This section may not be  
8                   construed as establishing any private right of action.

9                   “(f) DEFINITION.—For purposes of this section, the  
10                  term ‘person’ includes governmental entities.


11                  “(g) SUNSET.—This section and section 301(bb) do  
12                  not apply to any activity described in subsection (a) that  
13                  occurs on or after the expiration of the 10-year period be-  
14                  ginning on the date of the enactment of the Cloning Prohi-  
15                  bition Act of 2001.”.

16                  (b) PROHIBITED ACTS.—

17                   (1) IN GENERAL.—Section 301 of the Federal  
18                   Food, Drug, and Cosmetic Act (21 U.S.C. 331) is  
19                   amended by adding at the end the following:

20                   “(bb) The violation of section 1001(a), or the failure  
21                   to register in accordance with section 1001(c).”.

22                   (2) CRIMINAL PENALTY.—Section 303(b) of the  
23                   Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
24                   333(b)) is amended by adding at the end the fol-  
25                   lowing:



1           “(7) Notwithstanding subsection (a), any person who  
2 violates section 301(bb) shall be imprisoned not more than  
3 10 years or fined in accordance with title 18, United  
4 States Code, or both.”.

5           (3) CIVIL PENALTY.—Section 303 of the Fed-  
6 eral Food, Drug, and Cosmetic Act (21 U.S.C. 333)  
7 is amended by adding at the end the following:

8           “(h)(1) Any person who violates section 301(bb) shall  
9 be liable to the United States for a civil penalty in an  
10 amount not to exceed the greater of—

11                   “(A) \$1,000,000; or

12                   “(B) an amount equal to the amount of any  
13 gross pecuniary gain derived from such violation  
14 multiplied by 2.

15           “(2) Paragraphs (3) through (5) of subsection (g)  
16 apply with respect to a civil penalty under paragraph (1)  
17 of this subsection to the same extent and in the same man-  
18 ner as such paragraphs (3) through (5) apply with respect  
19 to a civil penalty under paragraph (1) or (2) of subsection  
20 (g).”.

21           (4) FORFEITURE.—Section 303 of the Federal  
22 Food, Drug, and Cosmetic Act, as amended by para-  
23 graph (3), is amended by adding at the end the fol-  
24 lowing:



1 “(i) Any property, real or personal, derived from or  
2 used to commit a violation of section 301(bb), or any prop-  
3 erty traceable to such property, shall be subject to for-  
4 feiture to the United States.”.

5 **SEC. 3. STUDY BY INSTITUTE OF MEDICINE.**

6 (a) IN GENERAL.—The Secretary of Health and  
7 Human Services (referred to in this section as the “Sec-  
8 retary”) shall request the Institute of Medicine to enter  
9 into an agreement with the Secretary under which such  
10 Institute conducts a study to—

11 (1) review the current state of knowledge about  
12 the biological properties of stem cells obtained from  
13 embryos, fetal tissues, and adult tissues;

14 (2) evaluate the current state of knowledge  
15 about biological differences among stem cells ob-  
16 tained from embryos, fetal tissues, and adult tissues  
17 and the consequences for research and medicine; and

18 (3) assess what is currently known about the  
19 ability of stem cells to generate neurons, heart, kid-  
20 ney, blood, liver and other tissues and the potential  
21 clinical uses of these tissues.

22 (b) OTHER ENTITIES.—If the Institute of Medicine  
23 declines to conduct the study described in subsection (a),  
24 the Secretary shall enter into an agreement with another



1 appropriate public or nonprofit private entity to conduct  
2 the study.

3 (c) REPORT.—The Secretary shall ensure that, not  
4 later than three years after the date of the enactment of  
5 this Act, the study required in subsection (a) is completed  
6 and a report describing the findings made in the study  
7 is submitted to the Committee on Energy and Commerce  
8 in the House of Representatives and the Committee on  
9 Health, Education, Labor, and Pensions in the Senate.

